Laboratory Co. of America (NYSE:LH) Stock Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on March 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Revvity (NYSE:RVTY) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of Laboratory Co. of America (NYSE:LH) on 2/28/2025.
• Purchased $15,001 – $50,000 in shares of Corpay (NYSE:CPAY) on 2/28/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/27/2025.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 2/22/2025.
• Purchased $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/22/2025.

Laboratory Co. of America Price Performance

NYSE:LH opened at $233.97 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The firm has a market cap of $19.58 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $258.59. The company’s 50-day moving average price is $245.16 and its two-hundred day moving average price is $234.28.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, equities analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 32.65%.

Hedge Funds Weigh In On Laboratory Co. of America

A number of hedge funds and other institutional investors have recently made changes to their positions in LH. Graney & King LLC bought a new stake in Laboratory Co. of America during the 4th quarter worth approximately $26,000. SouthState Corp acquired a new position in Laboratory Co. of America in the 3rd quarter worth $28,000. Fortitude Family Office LLC increased its holdings in Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 127 shares during the period. Finally, Human Investing LLC bought a new stake in shares of Laboratory Co. of America in the fourth quarter valued at about $39,000. 95.94% of the stock is owned by institutional investors.

Insider Transactions at Laboratory Co. of America

In related news, EVP Der Vaart Sandra D. Van sold 1,314 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the completion of the transaction, the executive vice president now owns 2,171 shares in the company, valued at approximately $545,572.30. This represents a 37.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Amy B. Summy sold 226 shares of Laboratory Co. of America stock in a transaction on Monday, February 24th. The shares were sold at an average price of $250.40, for a total transaction of $56,590.40. Following the completion of the sale, the chief marketing officer now owns 4,544 shares in the company, valued at $1,137,817.60. The trade was a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,500 shares of company stock valued at $3,577,572 over the last three months. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on LH. Jefferies Financial Group upped their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Barclays decreased their price target on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Piper Sandler boosted their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, UBS Group reduced their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $268.38.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.